An interventional study of Human milk and emollient: Apobase creme® (Actavis Norway AS) and Emollient: Apobase creme® (Actavis Norway AS) in Atopic Eczema, sponsored by Oslo University Hospital. Completed. Open to participants aged Up to 6 Years. Per ClinicalTrials.gov, last updated 2015-03-06.
Sponsored by Oslo University Hospital · Not applicable, Interventional, and Treatment
The aim of this small pilot study is to assess the potential effects and risks of applying fresh human milk locally on eczema spots in children with atopic eczema. This is a split body, controlled, randomized and physician blinded pilot study, of children with atopic eczema with two similar contralateral eczema spots having a mother breastfeeding the child or a sibling. Fresh expressed milk and emollient is to be applied on the intervention spot and emollient alone on the control area, three times a day for four weeks. Severity and area of the eczema spots is evaluated weekly, and samples from milk and the spots were analysed weekly with respect to bacterial colonisation.
1,443 studies on the registry are indexed under Dermatitis, Atopic; 253 are open to participants now.
This study's enrollment of 9 is below the median of 83 across 1,143 interventional studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →Oslo University Hospital is the lead sponsor of 830 studies on the registry; 146 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Human milk and emollient: Apobase creme® (Actavis Norway AS)
Other: Human milk and emollient: Apobase creme® (Actavis Norway AS) · Other: Emollient: Apobase creme® (Actavis Norway AS)
Emollient: Apobase creme® (Actavis Norway AS)
Other: Emollient: Apobase creme® (Actavis Norway AS)
Topical application of human milk followed by emollient
Topical application of emollient
Proportional change in area of the eczema spot from baseline
The primary outcome was proportional change in area (cm2) of the eczema spot from baseline, as measured by Visitrak™ (Smith \& Nephew), a portable device used to measure the area of wounds.
Time frame: four weeks
Transmission of bacteria from mother's milk to eczema spots in the child
The secondary outcome was to assess transmission of bacteria from mother's milk to eczema spots in the child.
Time frame: four weeks
No study locations are listed for this record.
The record gives a start of Oct 2008, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.